Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma

Research output: Contribution to journalArticlepeer-review

Abstract

Paclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (KS) patients. To date, only one patient with classical KS and treated with standard dose (175 mg/m2) 3-weekly paclitaxel as first line therapy has been reported in the literature. Herein, the first case is presented of a patient with anthracycline-refractory classical KS who was treated with standard dose 3-weekly and paclitaxel after five cycles of therapy achieved a partial response according to the AIDS Clinical Trials Group criteria.

Original languageEnglish
Pages (from-to)675-676
Number of pages2
JournalAnticancer Research
Volume29
Issue number2
Publication statusPublished - Feb 2009

Keywords

  • Anthracycline-refractory
  • Kaposi's sarcoma
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this